TTR and cardiomyopathy: Tafamidis is an analog of the non-steroidal anti-inflammatory drug diflunisal without nonsteroidal anti-inflammatory drug (NSAID) properties and was the first specific TTR-stabilizer to be approved by the FDA (May 2019) for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) [7].